Latest International Markets News

Island Pharmaceuticals has raised $3.6 million through a strategic share placement to advance its lead antiviral drug ISLA-101’s clinical development and broaden its asset portfolio ahead of pivotal Phase 2a/b trial results.

Spacetalk Ltd reports robust 3QFY25 results, showcasing strong revenue growth and a sharp reduction in losses as it pivots to a subscription-driven family safety platform.

TZ Limited has received a second purchase order from Wesco Anixter on behalf of Microsoft, reinforcing its growing role in global data centre security deployments. The combined orders now total approximately AUD 585,000, highlighting strong momentum in TZ’s expansion across key international markets.

OFX Limited reported a resilient FY25 with steady revenue and strong cash flow, while advancing its New Client Platform and strategic market expansion despite economic headwinds.

HeraMED faces a setback as Broward Health discontinues its HeraCARE platform amid Medicaid funding cuts, prompting a strategic pivot with new leadership and partnerships to accelerate US growth.

RooLife Group Ltd (ASX:RLG) has secured its first $475,000 solar product order from India, marking a significant step in its global renewable energy expansion. This milestone underscores RLG’s unique model blending Chinese manufacturing with international marketing and distribution.

Urbanise.com Ltd has partnered with NAB in a landmark deal where NAB acquires a 15% stake to integrate its banking services into Urbanise’s cloud-based strata management platform, aiming to launch a new solution in early 2026.

GrainCorp Limited reported robust first-half results for FY25, driven by a large East Coast Australia crop and solid operational execution, prompting an upgrade to full-year earnings guidance and an expanded share buy-back program.

Xero Limited has reported a robust FY25 with 23% revenue growth and a Rule of 40 score exceeding 44%, underscoring its balanced approach to growth and profitability.

Xero Limited reported a robust FY25 with 23% revenue growth to NZ$2.1 billion and a 30% rise in net profit, driven by strategic investments in AI and product innovation. Leadership changes and a CEO pay review underscore the company’s global ambitions.

EBR Systems has won FDA approval for its pioneering leadless WiSE CRT System, setting the stage for a phased US commercial rollout. The company also secured key Medicare reimbursement pathways and expanded manufacturing capacity, though financial sustainability remains a concern.

Life360’s Q1 2025 results reveal robust revenue growth, expanding profitability, and a bullish outlook for FY 2025, driven by a scalable freemium model and international expansion.